Larsen J S, Schmidt T A, Bundgaard H, Kjeldsen K
Department of Medicine B, Heart Centre, Rigshospitalet, National University Hospital, Copenhagen, Denmark.
Mol Cell Biochem. 1997 Apr;169(1-2):85-93. doi: 10.1023/a:1006851411650.
Myocardial Na+,K(+)-ATPase was studied in patients with aortic valve disease, and myocardial Na+,K(+)- and Ca(2+)-ATPase were assessed in spontaneously hypertensive rats (SHR) and hereditary cardiomyopathic hamsters using methods ensuring high enzyme recovery. Na+,K(+)-ATPase was quantified by [3H]ouabain binding to intact myocardial biopsies from patients with aortic valve disease. Aortic stenosis, regurgitation and a combination hereof were compared with normal human heart and were associated with reductions of left ventricular [3H]ouabain binding site concentration (pmol/g wet weight) of 56, 46 and 60%, respectively (p < 0.01). Na+,K(+)- and Ca(2+)-ATPases were quantified by K(+)- and Ca(2+)-dependent p-nitrophenyl phosphatase (pNPPase) activity determinations in crude myocardial homogenates from SHR and hereditary cardiomyopathic hamsters. When SHR were compared to age-matched Wistar Kyoto (WKY) rats an increase in heart-body weight ratio of 75% (p < 0.001) was associated with reductions of K(+)- and Ca(2+)-dependent pNPPase activities (mumol/min/g wet weight) of 42 (p < 0.01) and 27% (p < 0.05), respectively. When hereditary cardiomyopathic hamsters were compared to age-matched Syrian hamsters an increase in heart-body weight ratio of 69% (p < 0.001) was found to be associated with reductions in K(+)- and Ca(2+)-dependent pNPPase activities of 50 (p < 0.001) and 26% (p = 0.05), respectively. The reductions in Na+,K(+)- and Ca(2+)-ATPases were selective in relation to overall protein content and were not merely the outcome of increased myocardial mass relative to Na+,K(+)- and Ca(2+)-pumps. In conclusion, myocardial hypertrophy is in patients associated with reduced Na+,K(+)-ATPase concentration and in rodents with reduced Na+,K(+)- and Ca(2+)-ATPase concentrations. This may be of importance for development of heart failure and arrhythmia in hypertrophic heart disease.
我们使用确保高酶回收率的方法,对主动脉瓣疾病患者的心肌钠钾ATP酶进行了研究,并对自发性高血压大鼠(SHR)和遗传性心肌病仓鼠的心肌钠钾ATP酶及钙ATP酶进行了评估。通过[3H]哇巴因与主动脉瓣疾病患者完整心肌活检组织的结合来定量钠钾ATP酶。将主动脉瓣狭窄、反流及其组合与正常人心进行比较,发现它们分别使左心室[3H]哇巴因结合位点浓度(pmol/g湿重)降低了56%、46%和60%(p<0.01)。通过测定SHR和遗传性心肌病仓鼠心肌粗匀浆中钾依赖性和钙依赖性对硝基苯磷酸酶(pNPPase)活性来定量钠钾ATP酶和钙ATP酶。当将SHR与年龄匹配的Wistar Kyoto(WKY)大鼠进行比较时,心脏体重比增加75%(p<0.001),同时钾依赖性和钙依赖性pNPPase活性(μmol/min/g湿重)分别降低42%(p<0.01)和27%(p<0.05)。当将遗传性心肌病仓鼠与年龄匹配的叙利亚仓鼠进行比较时,发现心脏体重比增加69%(p<0.001),同时钾依赖性和钙依赖性pNPPase活性分别降低50%(p<0.001)和26%(p=0.05)。钠钾ATP酶和钙ATP酶的降低相对于总蛋白含量具有选择性,并非仅仅是相对于钠钾泵和钙泵而言心肌质量增加的结果。总之,在患者中,心肌肥厚与钠钾ATP酶浓度降低有关;在啮齿动物中,心肌肥厚与钠钾ATP酶和钙ATP酶浓度降低有关。这可能对肥厚性心脏病中心力衰竭和心律失常的发生具有重要意义。